Amgen scraps trials of drug for advanced stomach cancer

Nov 24 (Reuters) - Amgen Inc on Monday said it will scrap all trials of its experimental treatment rilotumumab in patients with advanced stomach cancer, after a safety monitoring board associated it with a higher incidence of deaths.